Late-breaking Data From PROMISE I Study On LimFlow System Confirm Excellent Sustained Outcomes In Patients With No-option Chronic Limb-threatening Ischemia

SAN JOSE, Calif. and LAS VEGAS: SAN JOSE, Calif. and LAS VEGAS, Oct. 7, 2021 /PRNewswire/ -- LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), on Wednesday announced 24-month results from the...

Click to view original post